Mendelian Randomization: GLP-1 Heart Failure Protection Goes Beyond Weight and Glucose Control | Research

The takeaway

Mendelian randomization confirmed GLP-1R activation reduces heart failure risk (OR 0.50), mediated primarily by BMI reduction but with residual direct cardioprotection persisting after BMI and T2D adjustment.

Direct heart protection
After statistically removing weight loss and diabetes effects, GLP-1 drugs still significantly protect against heart failure — proving direct cardiac benefit

What the researchers found

GLP-1R activation → HF: OR 0.50 (IVW). Primary mediator: BMI (67.2%), T2D (45%). After BMI adjustment: OR 0.59 (significant). After T2D adjustment: OR 0.51 (significant). Residual direct cardioprotection confirmed.

Why it matters

Proving direct cardioprotection beyond weight/glucose effects supports GLP-1 drug use for heart failure regardless of metabolic status.

How the study worked

Two-sample cis-Mendelian randomization using HbA1c as biomarker, 1,665,481 participants, IVW and MR-RAPS primary analyses, MR-BMA mediation, multivariable cis-MR with PC-GMM, and network cis-MR.

What this study cannot tell us

MR assumptions may be violated. HbA1c as biomarker has limitations. Cannot identify specific direct mechanisms.

How to read the evidence

Large-scale Mendelian randomization (1.67M participants) with multiple sensitivity analyses. Closest to causal evidence without an RCT.

When this study was published

Published in 2025.

The bigger picture

This genetic evidence establishes that GLP-1 drugs have intrinsic heart-protective properties independent of their metabolic effects — supporting expansion to non-diabetic HF.

Questions still open

Should GLP-1 drugs be trialed for HF in lean, non-diabetic patients?
What direct cardiac mechanisms explain the residual protection?
Does the cardioprotection extend to HFpEF specifically?

Common questions

Do GLP-1 drugs protect the heart directly, or just through weight loss?

Both. This genetic study proved that GLP-1 drugs halve heart failure risk — weight loss explains part of this, but significant heart protection remains even after accounting for weight and blood sugar effects.

Should non-diabetic heart failure patients take GLP-1 drugs?

This genetic evidence supports testing that idea. The direct cardioprotection independent of metabolic effects suggests GLP-1 drugs could benefit heart failure patients regardless of diabetes or obesity status.

Read the original research

GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.

European heart journal

View on PubMed ↗Publisher’s paper ↗

Citation

Hu, Yiqing; Zhao, Yongchao; Dai, Neng; Zhou, You; Yao, Yunqian; Li, Ziang; Cai, Wufeng; Xiong, Weidong; Song, Shuai; Deng, Xin; Yin, Jiasheng; Zhao, Xin; Weng, Xinyu; Li, Chenguang; Sun, Aijun; Qian, Juying; Lu, Hao; Ge, Junbo. (2026). GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.. European heart journal. https://doi.org/10.1093/eurheartj/ehaf1066